We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Alphatec Spine Enters Into Exclusive Distribution Agreement with Parcell Spine

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alphatec Spine Enters Into Exclusive Distribution Agreement with Parcell Spine"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Alphatec Holdings, Inc. announced that it has entered into an exclusive distribution agreement with Parcell Spine, LLC, pursuant to which Parcell will license and supply Alphatec Spine with Parcell's proprietary adult stem cells for the treatment of spinal disorders.

The stem cell, which Parcell commercially calls the ELA stem cell, is a unique adult stem cell that possesses self-renewal and bone regenerative capabilities. The cell is isolated from healthy, living adult donors. The ELA stem cell is highly concentrated in that these cells are derived from adult donors using Parcell's proprietary isolation method that has the potential to yield up to six hundred times more cells than a similar volume of mesenchymal stem cells harvested from bone marrow.

The US spinal Biologics market is estimated to be more than $1.5 Billion in 2010.

"The addition of an osteoprogenitor stem cell will provide Alphatec with an excellent position in the growing market of stem cell therapies for treating disorders of the spine, and will be a strong complement to the other innovative technologies in our core fusion and aging spine portfolios," said Dirk Kuyper, the Company's President and CEO.

Mr. Kuyper added, "We are expecting to release this product in the second half of 2010, and we could drive meaningful revenue from this product in 2011. We have been investing heavily into building out our biologics platform to support both our core fusion and aging spine portfolios of products. This product, our Profuse scaffold and the recently announced distribution agreement with ETEX Corporation, are all examples of our focus on providing biologic solutions to improving fusion rates."